Subcutaneous teicoplanin in staphylococcal bone and joint infections

•The use of subcutaneous teicoplanin was assessed in 40 patients presenting with staphylococcal bone and joint infection, with three injections per week for a third of them. Trough levels meeting the required pharmacological objectives (TL≥15mg/L) were obtained, without any significant difference between the subcutaneous and intravenous routes, and good tolerability was observed. Subcutaneous teicoplanin could be used as an alternative for the treatment of bone and joint infections, mainly in frail patients. We aimed to describe the use of subcutaneous teicoplanin as an alternative for the treatment of staphylococcal bone and joint infections. A retrospective multicentric cohort (2002–2015) was conducted with patients receiving subcutaneous teicoplanin for a staphylococcal bone and joint infection. Forty patients were assessed. A median loading dose of 9.4 mg/kg/12h (IQR, 6.1–13.1) was administered to 35 patients, subcutaneously for 18 of them. Thirteen of these patients received three injections per week. No excess risk of failure was identified. The trough level was not significantly different between the various routes (p=0.462), and was significantly higher if the loading dose was≥9 mg/kg/injection (p